Antibodies are promising post-exposure therapies against emerging viruses, but which antibody features and in vitro assays best forecast protection are unclear. Our international consortium systematically evaluated antibodies against Ebola virus (EBOV) using multidisciplinary assays. For each antibody, we evaluated epitopes recognized on the viral surface glycoprotein (GP) and secreted glycoprotein (sGP), readouts of multiple neutralization assays, fraction of virions left un-neutralized, glycan structures, phagocytic and natural killer cell functions elicited, and in vivo protection in a mouse challenge model. Neutralization and induction of multiple immune effector functions (IEFs) correlated most strongly with protection. Neutralization predominantly occurred via epitopes maintained on endosomally cleaved GP, whereas maximal IEF mapped to epitopes farthest from the viral membrane. Unexpectedly, sGP cross-reactivity did not significantly influence in vivo protection. This comprehensive dataset provides a rubric to evaluate novel antibodies and vaccine responses and a roadmap for therapeutic development for EBOV and related viruses.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6102396 | PMC |
| http://dx.doi.org/10.1016/j.cell.2018.07.033 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Vector induced humoral responses after rVSVΔG-ZEBOV-GP immunization identify vaccinated individuals and correlate with Ebola virus glycoprotein antibodies.
J Infect Dis
December 2024
Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Background: The robustness and persistence of vaccine antigen-induced antibodies are often used as proxy indicators of vaccine efficacy, but immune responses to vaccine vectors are typically less well-defined. Our study considered the kinetics of immunoglobulin (IgG) responses against the vector (vesicular stomatitis Indiana virus [VSIV]) nucleoprotein (N) and the inserted antigen (Ebola virus [EBOV]) glycoprotein (GP1,2) components of the rVSVΔG-ZEBOV-GP (rVSV-ZEBOV) vaccine and evaluated their use as biomarkers to confirm self-reported vaccination status.
Methods: From the Partnership for Research on Ebola Virus in Liberia (PREVAIL) I clinical trial (NCT02344407), we randomly selected 212 participants who received rVSV-ZEBOV (n=107) or placebo (n=105).
A Phase 1 randomized trial of homologous and heterologous filovirus vaccines with a late booster dose.
NPJ Vaccines
December 2024
Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
Filoviruses, including Ebola, Marburg, Sudan, and Taï Forest viruses, are zoonotic pathogens that can cause severe viral hemorrhagic fever and death. Developing vaccines that provide durable, broad immunity against multiple filoviruses is a high global health priority. In this Phase 1 trial, we enrolled 60 healthy U.
View Article and Find Full Text PDFDiscovery of Nanosota-EB1 and -EB2 as Novel Nanobody Inhibitors Against Ebola Virus Infection.
PLoS Pathog
December 2024
Department of Pharmacology, University of Minnesota Medical School, Minneapolis, Minnesota, United States of America.
The Ebola filovirus (EBOV) poses a serious threat to global health and national security. Nanobodies, a type of single-domain antibody, have demonstrated promising therapeutic potential. We identified two anti-EBOV nanobodies, Nanosota-EB1 and Nanosota-EB2, which specifically target the EBOV glycoprotein (GP).
View Article and Find Full Text PDFImmunochromatographic Lateral Flow Assays to Detect Filovirus Nucleoproteins.
Methods Mol Biol
November 2024
Division of Global Epidemiology, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
The recent large outbreaks of Ebola virus disease in West Africa and the Democratic Republic of the Congo have highlighted the need for rapid diagnostic tests to control this disease. In this chapter, the development of immunochromatographic lateral flow assays to detect filovirus nucleoproteins is described as an example of designing rapid diagnostic tests.
View Article and Find Full Text PDFQuantification of Filovirus Soluble Glycoprotein Using a Sandwich ELISA.
Methods Mol Biol
November 2024
National Research Center for the Control and Prevention of Infectious Diseases, Nagasaki University, Nagasaki, Japan.
Sandwich enzyme-linked immunosorbent assays (ELISAs), which quantify antigens captured between two layers of antibodies, are sensitive and fundamental tools used to diagnose diseases, evaluate the effects of countermeasures, and quantify target proteins. Many filoviruses use transcriptional editing to express three different glycoproteins (GPs) from the GP gene. The main product transcribed from the GP gene, the soluble glycoprotein (sGP), is detected at high levels in the blood during the acute phase of infection and correlates with viremia, making it an attractive target for molecular diagnostics.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!